By employing a concept known as cancer-activated lectin multivalency, we can generate protein therapeutics that can target metastatic cancer cells with unmatched specificity. This groundbreaking approach has opened the door for us to bring forward the next generation of Migrastatics from concept to reality. The motivation behind our work stems from the fact that prevention is often more effective than treatment. With our technology, we aim to put cancer survivors back in the driver’s seat to be more proactive about living a longer, healthier life.
Our vision is to deliver first-in-class preventative medicines that can stop the spread and onset of metastatic tumors. We are currently focused on bringing forward candidates to be used by breast, ovarian, and colorectal cancer survivors to help reduce their chances of recurrence. Our technology is also meant to be safe, so they will not harshly impact a patient’s quality of life as they look to take back their lives.
OUR PIPELINE